<?xml version='1.0' encoding='utf-8'?>
<document id="22735460"><sentence text="Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results."><entity charOffset="20-30" id="DDI-PubMed.22735460.s1.e0" text="fingolimod" /><entity charOffset="32-38" id="DDI-PubMed.22735460.s1.e1" text="FTY720" /><pair ddi="false" e1="DDI-PubMed.22735460.s1.e0" e2="DDI-PubMed.22735460.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s1.e0" e2="DDI-PubMed.22735460.s1.e1" /></sentence><sentence text="Fingolimod has a novel mechanism of action in multiple sclerosis, being a first-in-class sphingosine 1-phosphate receptor modulator"><entity charOffset="0-10" id="DDI-PubMed.22735460.s2.e0" text="Fingolimod" /><entity charOffset="89-112" id="DDI-PubMed.22735460.s2.e1" text="sphingosine 1-phosphate" /><pair ddi="false" e1="DDI-PubMed.22735460.s2.e0" e2="DDI-PubMed.22735460.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s2.e0" e2="DDI-PubMed.22735460.s2.e1" /></sentence><sentence text=" Because of a potential risk of fetal toxicity based on animal studies, women of childbearing potential are advised to take effective contraceptive measures during and for 2 months after stopping fingolimod therapy"><entity charOffset="196-206" id="DDI-PubMed.22735460.s3.e0" text="fingolimod" /></sentence><sentence text=" To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interaction study of fingolimod with ethinylestradiol/levonorgestrel was performed in healthy female volunteers"><entity charOffset="98-108" id="DDI-PubMed.22735460.s4.e0" text="fingolimod" /><entity charOffset="165-175" id="DDI-PubMed.22735460.s4.e1" text="fingolimod" /><entity charOffset="181-197" id="DDI-PubMed.22735460.s4.e2" text="ethinylestradiol" /><entity charOffset="198-212" id="DDI-PubMed.22735460.s4.e3" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e0" e2="DDI-PubMed.22735460.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e0" e2="DDI-PubMed.22735460.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e0" e2="DDI-PubMed.22735460.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e0" e2="DDI-PubMed.22735460.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e1" e2="DDI-PubMed.22735460.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e1" e2="DDI-PubMed.22735460.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e1" e2="DDI-PubMed.22735460.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e2" e2="DDI-PubMed.22735460.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22735460.s4.e2" e2="DDI-PubMed.22735460.s4.e3" /></sentence><sentence text="" /><sentence text="To assess the interaction between fingolimod 0"><entity charOffset="34-44" id="DDI-PubMed.22735460.s6.e0" text="fingolimod" /></sentence><sentence text="5 mg once daily and ethinylestradiol 30 μg/ levonorgestrel 150 μg once daily at a steady state"><entity charOffset="20-36" id="DDI-PubMed.22735460.s7.e0" text="ethinylestradiol" /><entity charOffset="44-58" id="DDI-PubMed.22735460.s7.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22735460.s7.e0" e2="DDI-PubMed.22735460.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s7.e0" e2="DDI-PubMed.22735460.s7.e1" /></sentence><sentence text="" /><sentence text="31 healthy women received the combined OC only on Days 1 - 14, followed by OC plus fingolimod on Days 15 - 28"><entity charOffset="83-93" id="DDI-PubMed.22735460.s9.e0" text="fingolimod" /></sentence><sentence text="" /><sentence text="In the presence of fingolimod, ethinylestradiol pharmacokinetics were unchanged, and levonorgestrel maximum plasma concentration at steady state and area under the concentration-time curve during a dosing interval increased by factors of 1"><entity charOffset="19-29" id="DDI-PubMed.22735460.s11.e0" text="fingolimod" /><entity charOffset="31-47" id="DDI-PubMed.22735460.s11.e1" text="ethinylestradiol" /><entity charOffset="85-99" id="DDI-PubMed.22735460.s11.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22735460.s11.e0" e2="DDI-PubMed.22735460.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s11.e0" e2="DDI-PubMed.22735460.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s11.e0" e2="DDI-PubMed.22735460.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22735460.s11.e1" e2="DDI-PubMed.22735460.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s11.e1" e2="DDI-PubMed.22735460.s11.e2" /></sentence><sentence text="10 (90% CI 1" /><sentence text="05 - 1" /><sentence text="16) and 1" /><sentence text="22 (90% CI 1" /><sentence text="18 - 1" /><sentence text="27), respectively" /><sentence text="" /><sentence text="Fingolimod therapy does not alter the pharmacokinetics of the combined OC ethinylestradiol/ levonorgestrel to a clinically significant degree"><entity charOffset="0-10" id="DDI-PubMed.22735460.s19.e0" text="Fingolimod" /><entity charOffset="92-106" id="DDI-PubMed.22735460.s19.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.22735460.s19.e0" e2="DDI-PubMed.22735460.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s19.e0" e2="DDI-PubMed.22735460.s19.e1" /></sentence><sentence text=" Ethinylestradiol/levonorgestrel does not alter the pharmacokinetics of fingolimod"><entity charOffset="1-17" id="DDI-PubMed.22735460.s20.e0" text="Ethinylestradiol" /><entity charOffset="18-32" id="DDI-PubMed.22735460.s20.e1" text="levonorgestrel" /><entity charOffset="72-82" id="DDI-PubMed.22735460.s20.e2" text="fingolimod" /><pair ddi="false" e1="DDI-PubMed.22735460.s20.e0" e2="DDI-PubMed.22735460.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22735460.s20.e0" e2="DDI-PubMed.22735460.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s20.e0" e2="DDI-PubMed.22735460.s20.e2" /><pair ddi="false" e1="DDI-PubMed.22735460.s20.e1" e2="DDI-PubMed.22735460.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22735460.s20.e1" e2="DDI-PubMed.22735460.s20.e2" /></sentence><sentence text=" Women receiving fingolimod therapy are able to use a combined OC as a means of effective birth control"><entity charOffset="17-27" id="DDI-PubMed.22735460.s21.e0" text="fingolimod" /></sentence><sentence text="" /></document>